{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:59:10Z","timestamp":1767650350836,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40263-020-00753-1","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T15:03:56Z","timestamp":1598627036000},"page":"1015-1024","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"34","author":[{"given":"Yanbo","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bixi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zilan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7517-7036","authenticated-orcid":false,"given":"Zhouqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"issue":"1","key":"753_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.molmed.2006.11.005","volume":"13","author":"PJ Goadsby","year":"2007","unstructured":"Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007;13(1):39\u201344.","journal-title":"Trends Mol Med"},{"issue":"1","key":"753_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","journal-title":"Cephalalgia"},{"issue":"12","key":"753_CR3","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s10072-016-2705-8","volume":"37","author":"A Raggi","year":"2016","unstructured":"Raggi A, Covelli V, Schiavolin S, Giovannetti AM, Cerniauskaite M, Quintas R, et al. Psychosocial difficulties in patients with episodic migraine: a cross-sectional study. Neurol Sci. 2016;37(12):1979\u201386.","journal-title":"Neurol Sci"},{"issue":"11","key":"753_CR4","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/j.1468-2982.2008.01648.x","volume":"28","author":"PJ Koehler","year":"2008","unstructured":"Koehler PJ, Tfelt-Hansen PC. History of methysergide in migraine. Cephalalgia. 2008;28(11):1126\u201335.","journal-title":"Cephalalgia"},{"issue":"3","key":"753_CR5","first-page":"124","volume":"4","author":"K Long","year":"1993","unstructured":"Long K, Long R. Sumatriptan for the treatment of acute migraine headache. Nurse Pract Forum. 1993;4(3):124\u20135.","journal-title":"Nurse Pract Forum"},{"issue":"2","key":"753_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553\u2013622.","journal-title":"Physiol Rev"},{"issue":"10","key":"753_CR7","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1177\/0333102410375512","volume":"30","author":"MD Ferrari","year":"2010","unstructured":"Ferrari MD, Farkkila M, Reuter U, Pilgrim A, Davis C, Krauss M, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan: a randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170\u20138.","journal-title":"Cephalalgia"},{"issue":"13","key":"753_CR8","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1080\/14656566.2017.1361406","volume":"18","author":"B Raffaelli","year":"2017","unstructured":"Raffaelli B, Israel H, Neeb L, Reuter U. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine. Expert Opin Pharmacother. 2017;18(13):1409\u201315.","journal-title":"Expert Opin Pharmacother"},{"issue":"18","key":"753_CR9","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","volume":"79","author":"YN Lamb","year":"2019","unstructured":"Lamb YN. Lasmiditan: first approval. Drugs. 2019;79(18):1989\u201396.","journal-title":"Drugs"},{"issue":"1","key":"753_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1046\/j.1468-2982.1997.1701037.x","volume":"17","author":"H Massiou","year":"1997","unstructured":"Massiou H, Tzourio C, el Amrani M, Bousser MG. Verbal scales in the acute treatment of migraine: semantic categories and clinical relevance. Cephalalgia. 1997;17(1):37\u20139 (discussion 2).","journal-title":"Cephalalgia"},{"key":"753_CR11","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014."},{"key":"753_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JP, Borm GF. The Hartung\u2013Knapp\u2013Sidik\u2013Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian\u2013Laird method. BMC Med Res Methodol. 2014;14:25.","journal-title":"BMC Med Res Methodol"},{"key":"753_CR13","unstructured":"R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/."},{"issue":"5","key":"753_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","volume":"11","author":"M Farkkila","year":"2012","unstructured":"Farkkila M, Diener HC, Geraud G, Lainez M, Schoenen J, Harner N, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405\u201313.","journal-title":"Lancet Neurol"},{"issue":"24","key":"753_CR15","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91(24):e2222\u201332.","journal-title":"Neurology"},{"issue":"7","key":"753_CR16","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894\u2013904.","journal-title":"Brain"},{"issue":"12","key":"753_CR17","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1177\/0333102419859313","volume":"39","author":"EG Doty","year":"2019","unstructured":"Doty EG, Krege JH, Jin L, Raskin J, Halker Singh RB, Kalidas K. Sustained responses to lasmiditan: results from post-hoc analyses of two phase 3 randomized clinical trials for acute treatment of migraine. Cephalalgia. 2019;39(12):1569\u201376.","journal-title":"Cephalalgia"},{"issue":"10","key":"753_CR18","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/head.13636","volume":"59","author":"M Ashina","year":"2019","unstructured":"Ashina M, Vasudeva R, Jin L, Lombard L, Gray E, Doty EG, et al. Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: integrated results from 2 randomized double-blind placebo-controlled phase 3 clinical studies. Headache. 2019;59(10):1788\u2013801.","journal-title":"Headache"},{"issue":"1","key":"753_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12883-019-1420-5","volume":"19","author":"LS Loo","year":"2019","unstructured":"Loo LS, Plato BM, Turner IM, Case MG, Raskin J, Dowsett SA, et al. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurol. 2019;19(1):191.","journal-title":"BMC Neurol"},{"issue":"1","key":"753_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-019-1032-x","volume":"20","author":"LS Loo","year":"2019","unstructured":"Loo LS, Ailani J, Schim J, Baygani S, Hundemer HP, Port M, et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain. 2019;20(1):84.","journal-title":"J Headache Pain"},{"key":"753_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/cpdd.768","volume":"5","author":"M Tsai","year":"2020","unstructured":"Tsai M, Case M, Ardayfio P, Hochstetler H, Wilbraham D. Effects of lasmiditan on cardiovascular parameters and pharmacokinetics in healthy subjects receiving oral doses of propranolol. Clin Pharmacol Drug Dev. 2020;5:629\u201338.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"753_CR22","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/head.13544","volume":"59","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Krege JH, Lombard L, Asafu-Adjei JK, Dowsett SA, Raskin J, et al. Characterization of dizziness after lasmiditan usage: findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials. Headache. 2019;59(7):1052\u201362.","journal-title":"Headache"},{"issue":"4","key":"753_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/jcph.1543","volume":"60","author":"D Wilbraham","year":"2020","unstructured":"Wilbraham D, Berg PH, Tsai M, Liffick E, Loo LS, Doty EG, et al. Abuse potential of lasmiditan: a phase 1 randomized, placebo- and alprazolam-controlled crossover study. J Clin Pharmacol. 2020;60(4):495\u2013504.","journal-title":"J Clin Pharmacol"},{"issue":"Suppl. 4","key":"753_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/head.12601","volume":"55","author":"C Cameron","year":"2015","unstructured":"Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl. 4):221\u201335.","journal-title":"Headache"},{"issue":"1","key":"753_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s10194-016-0703-0","volume":"17","author":"H Xu","year":"2016","unstructured":"Xu H, Han W, Wang J, Li M. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain. 2016;17(1):113.","journal-title":"J Headache Pain"},{"issue":"8","key":"753_CR26","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","volume":"22","author":"MD Ferrari","year":"2002","unstructured":"Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633\u201358.","journal-title":"Cephalalgia"},{"issue":"10","key":"753_CR27","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/head.13179","volume":"57","author":"RB Lipton","year":"2017","unstructured":"Lipton RB, Reed ML, Kurth T, Fanning KM, Buse DC. Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2017;57(10):1507\u201321.","journal-title":"Headache"},{"issue":"5","key":"753_CR28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","volume":"44","author":"D Dodick","year":"2004","unstructured":"Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414\u201325.","journal-title":"Headache"},{"issue":"24","key":"753_CR29","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1111\/bph.14832","volume":"176","author":"E Rubio-Beltran","year":"2019","unstructured":"Rubio-Beltran E, Labastida-Ramirez A, Haanes KA, van den Bogaerdt A, Bogers A, Zanelli E, et al. Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan. Br J Pharmacol. 2019;176(24):4681\u201395.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"753_CR30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10194-011-0388-3","volume":"12","author":"A Negro","year":"2011","unstructured":"Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12(6):593\u2013601.","journal-title":"J Headache Pain"},{"issue":"4","key":"753_CR31","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1046\/j.1526-4610.2003.03073.x","volume":"43","author":"G Geraud","year":"2003","unstructured":"Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43(4):376\u201388.","journal-title":"Headache"},{"issue":"1","key":"753_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s10194-020-01088-4","volume":"21","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Lombard L, Ruff DD, Krege JH, Loo LS, Buchanan A, et al. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. J Headache Pain. 2020;21(1):20.","journal-title":"J Headache Pain"},{"issue":"11","key":"753_CR33","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/0333102419864132","volume":"39","author":"JL Brandes","year":"2019","unstructured":"Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, et al. Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019;39(11):1343\u201357.","journal-title":"Cephalalgia"},{"issue":"1","key":"753_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0333102419889350","volume":"40","author":"K Knievel","year":"2020","unstructured":"Knievel K, Buchanan AS, Lombard L, Baygani S, Raskin J, Krege JH, et al. Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia. 2020;40(1):19\u201327.","journal-title":"Cephalalgia"},{"key":"753_CR35","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3389\/fphar.2019.01577","volume":"10","author":"B Gao","year":"2019","unstructured":"Gao B, Yang Y, Wang Z, Sun Y, Chen Z, Zhu Y, et al. Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Front Pharmacol. 2019;10:1577.","journal-title":"Front Pharmacol"},{"issue":"5","key":"753_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40263-020-00715-7","volume":"34","author":"Y Yang","year":"2020","unstructured":"Yang Y, Chen M, Sun Y, Gao B, Chen Z, Wang Z. Safety and efficacy of ubrogepant for the acute treatment of episodic migraine: a meta-analysis of randomized clinical trials. CNS Drugs. 2020;34(5):463\u201371.","journal-title":"CNS Drugs"},{"issue":"4","key":"753_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40265-019-01069-1","volume":"79","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, et al. Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs. 2019;79(4):417\u201331.","journal-title":"Drugs"},{"issue":"1","key":"753_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40122-020-00159-3","volume":"9","author":"I Urits","year":"2020","unstructured":"Urits I, Clark G, An D, Wesp B, Zhou R, Amgalan A, et al. An evidence-based review of fremanezumab for the treatment of migraine. Pain Ther. 2020;9(1):195\u2013215.","journal-title":"Pain Ther"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00753-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-020-00753-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00753-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T23:20:02Z","timestamp":1630106402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-020-00753-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["753"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00753-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"type":"print","value":"1172-7047"},{"type":"electronic","value":"1179-1934"}],"subject":[],"published":{"date-parts":[[2020,8,28]]},"assertion":[{"value":"28 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Suzhou Health Talents Training Project (GSWS2019002).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yanbo Yang, Yue Sun, Bixi Gao, Zilan Wang, Zhouqing Chen, and Zhong Wang have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}